Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b Open-Label Single-Arm Study of Acalabrutinib in Chronic Lymphocytic Leukemia
2019-001573-89Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of acalabrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by AstraZeneca. Primary endpoint: Safety and tolerability (adverse events). Started Jun 2019; status: active.
02
Drugs
acalabrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2019-001573-89.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001573-89.